Lonza completes $4.5 bln specialty ingredients divestment - Reuters

The logo of Swiss pharmaceutical group Lonza is seen at its headquarters in Basel, Switzerland March 2, 2020. REUTERS/Arnd Wiegmann/File Photo

ZURICH, July 2 (Reuters) - Lonza (LONN.S) has completed the divestment of its specialty ingredients business to Bain Capital and Cinven for an enterprise value of 4.2 billion Swiss francs ($4.53 billion), the Swiss contract drug maker said on Friday.

The deal, announced in February, came as the Swiss contract drug manager pledged to focus on its faster-growing drugs and biotech unit.

"As the divestment of the Specialty Ingredients business completes, at Lonza we have an opportunity to consolidate our identity and redouble our focus on long-term growth," Chairman Albert Baehny said in a statement on Friday.

($1 = 0.9262 Swiss francs)

Reporting by Brenna Hughes Neghaiwi, editing by John Revill

Our Standards: The Thomson Reuters Trust Principles.

Adblock test (Why?)

"ingredients" - Google News
July 02, 2021 at 12:20PM
https://ift.tt/3qF8peh

Lonza completes $4.5 bln specialty ingredients divestment - Reuters
"ingredients" - Google News
https://ift.tt/2Qstat1
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update

Bagikan Berita Ini